XOMA Royalty Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that XOMA Royalty Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.15M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $28.49M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $4.76M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $6.03M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $38.16M | Mar 9, 2023 |
| FY2020 | Dec 31, 2020 | $27.58M | Mar 10, 2021 |
| FY2020 | Sep 30, 2020 | $557.0K | Mar 10, 2021 |
| FY2020 | Jun 30, 2020 | $444.0K | Mar 10, 2021 |
| FY2020 | Mar 31, 2020 | $804.0K | Mar 10, 2021 |
| FY2020 | Dec 31, 2019 | $422.0K | Mar 10, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.35M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $6.65M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $2.65M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $4.15M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $36.52M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $27.94M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $17.28M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $5.07M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $52.43M | Mar 7, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.71M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($13.82M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($40.83M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($17.10M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $15.80M | Mar 9, 2023 |
| FY2020 | Dec 31, 2020 | $22.67M | Mar 10, 2021 |
| FY2020 | Sep 30, 2020 | ($1.08M) | Mar 10, 2021 |
| FY2020 | Jun 30, 2020 | ($3.53M) | Mar 10, 2021 |
| FY2020 | Mar 31, 2020 | ($4.76M) | Mar 10, 2021 |
| FY2020 | Dec 31, 2019 | ($4.32M) | Mar 10, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.38M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($39.98M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($41.85M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($17.41M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $17.53M | Mar 9, 2023 |
| FY2020 | Dec 31, 2020 | $23.87M | Mar 10, 2021 |
| FY2020 | Sep 30, 2020 | ($2.69M) | Mar 10, 2021 |
| FY2020 | Jun 30, 2020 | ($3.15M) | Mar 10, 2021 |
| FY2020 | Mar 31, 2020 | ($5.62M) | Mar 10, 2021 |
| FY2020 | Dec 31, 2019 | ($4.00M) | Mar 10, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.71M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $2.88M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $143.0K | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $153.0K | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $171.0K | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $170.0K | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $1.25M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $1.68M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $7.88M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $44.23M | Mar 7, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $18.32M | Mar 16, 2017 |
| FY2016 | Dec 31, 2015 | $20.62M | Mar 16, 2017 |
| FY2016 | Dec 31, 2014 | $19.87M | Mar 16, 2017 |
| FY2015 | Dec 31, 2013 | $18.48M | Mar 9, 2016 |
| FY2014 | Dec 31, 2012 | $16.87M | Mar 11, 2015 |
| FY2013 | Dec 31, 2011 | $24.01M | Mar 12, 2014 |
| FY2012 | Dec 31, 2010 | $23.25M | Mar 12, 2013 |
| FY2011 | Dec 31, 2009 | $23.74M | Mar 14, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.87M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($13.75M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($18.16M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($12.88M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $22.68M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $10.09M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | ($285.0K) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($12.64M) | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $2.69M | Mar 7, 2019 |
| FY2013 | Dec 31, 2013 | ($45.92M) | Mar 12, 2014 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $20.0K | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $17.0K | Mar 17, 2025 |
| FY2021 | Dec 31, 2020 | $9.0K | Mar 8, 2022 |
| FY2019 | Dec 31, 2018 | $6.0K | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $8.0K | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $59.0K | Mar 7, 2018 |
| FY2017 | Dec 31, 2015 | $430.0K | Mar 7, 2018 |
| FY2016 | Dec 31, 2014 | $325.0K | Mar 16, 2017 |
| FY2015 | Dec 31, 2013 | $1.17M | Mar 9, 2016 |
| FY2014 | Dec 31, 2012 | $2.51M | Mar 11, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $272.70M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $221.28M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $234.30M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $140.38M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $166.56M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $125.29M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $95.72M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $63.79M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $44.94M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $28.68M | Mar 7, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $168.74M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $139.36M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $145.58M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $16.37M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $24.69M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $38.86M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $51.74M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $45.00M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $39.15M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $75.89M | Mar 7, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $83.94M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $61.90M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $88.72M | Mar 17, 2025 |
| FY2024 | Dec 31, 2022 | $124.01M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $141.88M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $86.42M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $43.99M | Mar 8, 2022 |
| FY2020 | Dec 31, 2018 | $18.79M | Mar 10, 2021 |
| FY2019 | Dec 31, 2017 | $5.79M | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | ($47.21M) | Mar 7, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.22B) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($1.24B) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($1.22B) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($1.18B) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($1.17B) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($1.18B) | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | ($1.19B) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($1.19B) | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | ($1.18B) | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | ($1.19B) | Mar 7, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $82.91M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $101.65M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $153.29M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $57.83M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $93.33M | Mar 9, 2023 |
| FY2018 | Dec 31, 2018 | $45.78M | Mar 7, 2019 |
| FY2018 | Dec 31, 2017 | $43.47M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $25.74M | Mar 7, 2018 |
| FY2017 | Dec 31, 2015 | $65.77M | Mar 7, 2018 |
| FY2017 | Dec 31, 2014 | $78.45M | Mar 7, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | $0 | Mar 8, 2024 |
| FY2020 | Dec 31, 2020 | $20.85M | Mar 10, 2021 |
| FY2019 | Dec 31, 2019 | $32.28M | Mar 10, 2020 |
| FY2016 | Dec 31, 2016 | $43.17M | Mar 16, 2017 |
| FY2016 | Dec 31, 2015 | $48.67M | Mar 16, 2017 |
| FY2015 | Dec 31, 2014 | $35.31M | Mar 9, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | (4) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 9, 2023 |
| FY2020 | Dec 31, 2020 | 1 | Mar 10, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 10, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 10, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 10, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 10, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | (4) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 9, 2023 |
| FY2020 | Dec 31, 2020 | 1 | Mar 10, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 10, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 10, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 10, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 10, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11.86M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | 11.95M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | 11.50M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 11.45M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | 11.32M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | 11.23M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | 9.76M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | 8.69M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | 8.25M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | 6.11M | Mar 7, 2018 |